Form 4/A for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2024-07-12 00:00:00 ET · period of report 2024-06-05 · accession 0001601830-24-000102 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2024-07-12 | 2024-06-05 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 908.7K | +12% | $0 |
| DA | 2024-07-12 | 2024-06-05 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | -100.0K | 6.33M | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-06-05 | C | A | 100,000 | $0.00 | 908,738 | D | — | — | (F3) This amendment corrects the amount of shares converted from Class B Common Stock to Class A Common Stock from 25,000 to 100,000 shares. |
| 2 | Derivative | Class B Common Stock | 2024-06-05 | C | D | 100,000 | $0.00 | 6,326,700 | D | $0.00 · — to — | 100,000 Class A Common Stock | (F4) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |